Autolus Therapeutics (AUTL) Current Leases (2019 - 2026)

Autolus Therapeutics (AUTL) has 7 years of Current Leases data on file, last reported at $4.6 million in Q4 2025.

• Quarterly Current Leases rose 52.27% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (up 52.27% YoY) and the FY2025 annual result came in at $4.6 million, up 52.27% from the prior year.
• Current Leases slipped to $4.6 million in Q4 2025, from $4.8 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $6.2 million in Q2 2023 to a low of $3.0 million in Q1 2025.
• A 5-year average of $4.3 million and a median of $4.3 million in 2021 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2023 — Current Leases jumped 55.97% — and 2024, when it plunged 40.67%.
• Tracing AUTL's Current Leases over 5 years: stood at $4.5 million in 2021, then climbed by 13.14% to $5.0 million in 2022, then climbed by 0.3% to $5.1 million in 2023, then sank by 40.67% to $3.0 million in 2024, then jumped by 52.27% to $4.6 million in 2025.
• The last three Current Leases figures came in at $4.6 million (Q4 2025), $4.8 million (Q3 2025), and $3.3 million (Q2 2025), per Business Quant data.